| Dr Rafael Baracaldo, MD | |
|
6400 Dutchmans Pkwy Ste 250, Louisville, KY 40205-3354 | |
| (502) 587-9660 | |
| (502) 540-5615 |
| Full Name | Dr Rafael Baracaldo |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 24 Years |
| Location | 6400 Dutchmans Pkwy Ste 250, Louisville, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013151968 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 04-37029 (Kansas) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | TP737 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fmc-south Central Louisville | Louisville, KY | Dialysis facility |
| Fmc - South Louisville | Louisville, KY | Dialysis facility |
| Davita - Meadows East | Louisville, KY | Dialysis facility |
| Fmc - Southwest | Valley station, KY | Dialysis facility |
| Baptist Health Louisville | Louisville, KY | Hospital |
| Norton Hospitals, Inc | Louisville, KY | Hospital |
| Jewish Hospital & St Mary's Healthcare | Louisville, KY | Hospital |
| Frankfort Regional Medical Center | Frankfort, KY | Hospital |
| Hardin Memorial Hospital | Elizabethtown, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nephrology Associates Of Kentuckiana Psc | 4183522618 | 35 |
| Nephrology Associates Of Kentuckiana Psc | 4183522618 | 35 |
News Archive
U.S. adolescents' high levels of poor health behaviors and unfavorable cardiovascular risk factors may increase their chances of heart disease as adults, according to new research in the American Heart Association journal Circulation.
Recent research indicates that school burnout among adolescents is shared with parental work burnout. Children of parents suffering from burnout are more likely than others to experience school burnout.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Inactivating a protective molecule in leukemic cells to make them more vulnerable to chemotherapy might also make healthy blood-forming cells more sensitive to the toxic effects of those same drugs.
By pinpointing the motor and language areas of the brain with functional magnetic resonance imaging (fMRI), surgeons can target brain tumors more effectively while reducing the risk of damaging important cognitive and motor processes.
› Verified 7 days ago
| Entity Name | Nephrology Associates Of Kentuckiana Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730161753 PECOS PAC ID: 4183522618 Enrollment ID: O20040204000026 |
News Archive
U.S. adolescents' high levels of poor health behaviors and unfavorable cardiovascular risk factors may increase their chances of heart disease as adults, according to new research in the American Heart Association journal Circulation.
Recent research indicates that school burnout among adolescents is shared with parental work burnout. Children of parents suffering from burnout are more likely than others to experience school burnout.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Inactivating a protective molecule in leukemic cells to make them more vulnerable to chemotherapy might also make healthy blood-forming cells more sensitive to the toxic effects of those same drugs.
By pinpointing the motor and language areas of the brain with functional magnetic resonance imaging (fMRI), surgeons can target brain tumors more effectively while reducing the risk of damaging important cognitive and motor processes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Rafael Baracaldo, MD 6400 Dutchmans Pkwy Ste 250, Louisville, KY 40205-3354 Ph: (502) 587-9660 | Dr Rafael Baracaldo, MD 6400 Dutchmans Pkwy Ste 250, Louisville, KY 40205-3354 Ph: (502) 587-9660 |
News Archive
U.S. adolescents' high levels of poor health behaviors and unfavorable cardiovascular risk factors may increase their chances of heart disease as adults, according to new research in the American Heart Association journal Circulation.
Recent research indicates that school burnout among adolescents is shared with parental work burnout. Children of parents suffering from burnout are more likely than others to experience school burnout.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Inactivating a protective molecule in leukemic cells to make them more vulnerable to chemotherapy might also make healthy blood-forming cells more sensitive to the toxic effects of those same drugs.
By pinpointing the motor and language areas of the brain with functional magnetic resonance imaging (fMRI), surgeons can target brain tumors more effectively while reducing the risk of damaging important cognitive and motor processes.
› Verified 7 days ago
Cindy J Code, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 3950 Kresge Way, Suite 303, Louisville, KY 40207 Phone: 502-896-1880 Fax: 502-896-1887 | |
Dr. Uchenna Loretta Ozor, M.D Nephrology Medicare: Accepting Medicare Assignments Practice Location: 200 E Chestnut St Bldg Suite303, Louisville, KY 40202 Phone: 502-629-5552 Fax: 502-629-3132 | |
Mohamed Hegazi, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 529 S Jackson St, Louisville, KY 40202 Phone: 502-562-4270 | |
Dr. Michael Patrick Krease, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1169 Eastern Pkwy Ste G58, Louisville, KY 40217 Phone: 502-452-9567 | |
Dr. Ramsey Nasri Nassar, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 6400 Dutchmans Pkwy, Ste 250, Louisville, KY 40205 Phone: 502-587-9660 Fax: 502-540-5615 | |
Jeanne M Thompson, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3 Audubon Plaza Dr, Ll2, Louisville, KY 40217 Phone: 502-636-8095 Fax: 502-636-8097 | |
Terrence P Donohue, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 3101 Poplar Level Rd Ste 101, Louisville, KY 40213 Phone: 502-636-7444 Fax: 502-636-7112 |